JP2016516068A5 - - Google Patents

Download PDF

Info

Publication number
JP2016516068A5
JP2016516068A5 JP2016503207A JP2016503207A JP2016516068A5 JP 2016516068 A5 JP2016516068 A5 JP 2016516068A5 JP 2016503207 A JP2016503207 A JP 2016503207A JP 2016503207 A JP2016503207 A JP 2016503207A JP 2016516068 A5 JP2016516068 A5 JP 2016516068A5
Authority
JP
Japan
Prior art keywords
substituted
group
unsubstituted
aryl
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503207A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516068A (ja
JP6572201B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/029723 external-priority patent/WO2014145068A1/en
Publication of JP2016516068A publication Critical patent/JP2016516068A/ja
Publication of JP2016516068A5 publication Critical patent/JP2016516068A5/ja
Application granted granted Critical
Publication of JP6572201B2 publication Critical patent/JP6572201B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503207A 2013-03-15 2014-03-14 眼疾患を処置するための組成物、製剤、および方法 Active JP6572201B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201361792868P 2013-03-15 2013-03-15
US201361792679P 2013-03-15 2013-03-15
US61/792,868 2013-03-15
US61/792,679 2013-03-15
US201361882048P 2013-09-25 2013-09-25
US201361882056P 2013-09-25 2013-09-25
US61/882,056 2013-09-25
US61/882,048 2013-09-25
US201461934570P 2014-01-31 2014-01-31
US61/934,570 2014-01-31
PCT/US2014/029723 WO2014145068A1 (en) 2013-03-15 2014-03-14 Compositions, formulations and methods for treating ocular diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019147238A Division JP6865254B2 (ja) 2013-03-15 2019-08-09 眼疾患を処置するための組成物、製剤、および方法

Publications (3)

Publication Number Publication Date
JP2016516068A JP2016516068A (ja) 2016-06-02
JP2016516068A5 true JP2016516068A5 (enExample) 2017-04-20
JP6572201B2 JP6572201B2 (ja) 2019-09-04

Family

ID=51529957

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016503207A Active JP6572201B2 (ja) 2013-03-15 2014-03-14 眼疾患を処置するための組成物、製剤、および方法
JP2019147238A Active JP6865254B2 (ja) 2013-03-15 2019-08-09 眼疾患を処置するための組成物、製剤、および方法
JP2021064106A Active JP7249374B2 (ja) 2013-03-15 2021-04-05 眼疾患を処置するための組成物、製剤、および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019147238A Active JP6865254B2 (ja) 2013-03-15 2019-08-09 眼疾患を処置するための組成物、製剤、および方法
JP2021064106A Active JP7249374B2 (ja) 2013-03-15 2021-04-05 眼疾患を処置するための組成物、製剤、および方法

Country Status (17)

Country Link
US (10) US9440963B2 (enExample)
EP (3) EP3607821B1 (enExample)
JP (3) JP6572201B2 (enExample)
KR (1) KR20150129019A (enExample)
CN (2) CN105307498B (enExample)
AU (2) AU2014233363B2 (enExample)
BR (1) BR112015023753A2 (enExample)
CA (1) CA2903871A1 (enExample)
ES (2) ES2928162T3 (enExample)
GB (3) GB2549865B (enExample)
HK (2) HK1206558A1 (enExample)
IL (2) IL240786B (enExample)
MX (1) MX371382B (enExample)
MY (1) MY171945A (enExample)
PH (2) PH12015502153B1 (enExample)
SG (1) SG11201507131WA (enExample)
WO (1) WO2014145068A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3252079B8 (en) 2006-04-07 2020-09-09 Aerpio Therapeutics LLC Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
SG10201505672TA (en) 2009-07-06 2015-09-29 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
ES2712989T3 (es) 2009-10-30 2019-05-17 Ix Biopharma Ltd Forma de dosificación sólida de disolución rápida
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
MY160066A (en) 2009-11-06 2017-02-15 Aerpio Therapeutics Inc Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
US20180092883A1 (en) * 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
CA2819549C (en) 2010-12-08 2019-09-10 Convatec Technologies Inc. Wound exudate system accessory
EP2648793B1 (en) 2010-12-08 2020-03-11 ConvaTec Technologies Inc. Integrated system for assessing wound exudates
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
CA2850824C (en) 2011-10-13 2023-01-03 Aerpio Therapeutics, Inc. Treatment of ocular disease
CN107669649A (zh) * 2012-10-11 2018-02-09 Ix生物制药有限公司 固体剂型
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
ES2928162T3 (es) * 2013-03-15 2022-11-15 Eyepoint Pharmaceuticals Inc Composiciones, formulaciones y métodos para tratar enfermedades oculares
EP3107542B1 (en) 2014-02-19 2019-05-01 Aerpio Therapeutics, Inc. Process for preparing n-benzyl-3-hydroxy-4-substituted-pyridin-2-(1h)-ones
EP3116503A4 (en) * 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9539245B2 (en) 2014-08-07 2017-01-10 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of Tie-2
EP3352856B1 (en) 2015-09-23 2021-08-18 Aerpio Pharmaceuticals, Inc. Activators of tie-2 for use in treating intraocular pressure
EP3364674B1 (en) * 2015-11-06 2019-10-09 Huawei Technologies Co., Ltd. Voice roaming method, mobility management network element, and access network element
WO2018017714A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
CN109996440A (zh) * 2016-10-21 2019-07-09 曼宁研究有限公司 Ve-ptp敲除
CN120058958A (zh) 2018-09-24 2025-05-30 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
AU2020259450A1 (en) * 2019-04-18 2021-11-18 EyePoint Pharmaceuticals, Inc. Methods of treating hypertension with activators of Tie-2
US11253502B2 (en) 2019-04-29 2022-02-22 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the Schlemm's canal
KR20250051157A (ko) 2019-06-05 2025-04-16 리제너론 파아마슈티컬스, 인크. 정밀 투여량 전달을 위한 디바이스 및 방법
US11413242B2 (en) 2019-06-24 2022-08-16 EyePoint Pharmaceuticals, Inc. Formulations of Tie-2 activators and methods of use thereof
CN114901278A (zh) 2019-10-29 2022-08-12 视点制药公司 Tie-2的小分子激活剂
JP2023530457A (ja) * 2020-06-16 2023-07-18 リプカ，エイミー 小分子ｖｅ－ｐｔｐ阻害剤
CN116940355A (zh) * 2020-12-18 2023-10-24 视点制药公司 用于制造tie-2的小分子激活剂的方法
WO2025128706A1 (en) * 2023-12-11 2025-06-19 Massachusetts Eye And Ear Infirmary Methods of using tie-2 activators

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078486A (en) 1989-10-13 1992-01-07 Evans David W Self-calibrating vision test apparatus
US5688781A (en) 1994-08-19 1997-11-18 Bristol-Myers Squibb Company Method for treating vascular leak syndrome
EP0821728B1 (en) 1995-04-06 2004-08-11 Regeneron Pharmaceuticals, Inc. Tie-2 ligands, methods of making and uses thereof
US20030040463A1 (en) 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
US6455031B1 (en) * 1997-06-18 2002-09-24 David G Davies Methods and compositions for controlling biofilm development
US5919813C1 (en) 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
US5980929A (en) 1998-03-13 1999-11-09 Johns Hopkins University, School Of Medicine Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
ES2199804T3 (es) 1999-03-26 2004-03-01 Regeneron Pharmaceuticals, Inc. Modulacion de la permeabilidad vascular por medio de activadores del receptor tie2.
US6455035B1 (en) * 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
WO2001097850A2 (en) 2000-06-23 2001-12-27 Schering Aktiengesellschaft Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
CA2431319A1 (en) * 2000-12-11 2002-06-20 Hiroto Bando Pharmaceutical composition having an improved water solubility
SE518981C2 (sv) 2000-12-14 2002-12-17 Shl Medical Ab Autoinjektor
US7166435B2 (en) * 2001-08-06 2007-01-23 The Quigley Corporation Compositions and methods for reducing the transmissivity of illnesses
US20030158199A1 (en) 2002-01-25 2003-08-21 Kylix, B.V. Novel compounds for inhibition of Tie-2
WO2003090686A2 (en) 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7091193B2 (en) * 2002-10-09 2006-08-15 Kosan Biosciences Incorporated Therapeutic formulations
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
US6946479B2 (en) 2002-11-09 2005-09-20 The Procter & Gamble Company N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
AU2003292838A1 (en) * 2002-12-27 2004-07-29 Kirin Beer Kabushiki Kaisha Therapeutic agent for wet age-related macular degeneration
US8178570B2 (en) * 2003-04-09 2012-05-15 Exelixis, Inc. Tie-2 modulators and methods of use
KR20160014775A (ko) * 2003-05-30 2016-02-11 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
US20050059639A1 (en) 2003-09-11 2005-03-17 Wei Edward T. Ophthalmic compositions and method for treating eye discomfort and pain
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
JP2008509085A (ja) * 2004-06-02 2008-03-27 バルティオン テクニリーネン トゥトキムスケスクス Ｔ細胞タンパク質チロシンホスファターゼの活性化方法およびそれに基づく治療方法
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
MX2008006379A (es) 2005-11-29 2009-03-03 Smithkline Beecham Corp Metodo de tratamiento.
EP1962903B1 (en) 2005-12-15 2013-03-13 MedImmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
KR20080101888A (ko) * 2006-02-09 2008-11-21 다이이찌 산쿄 가부시키가이샤 항암 의약 조성물
EP3252079B8 (en) 2006-04-07 2020-09-09 Aerpio Therapeutics LLC Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof
US20130023542A1 (en) 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) * 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
WO2008027013A2 (en) * 2006-08-29 2008-03-06 National Cancer Centre Combination of mtor antagonist and angiogenesis inhibitor for the treatment of cancer
EP2076290B1 (en) * 2006-10-27 2016-12-14 Sunnybrook Health Sciences Center Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
DK1932558T3 (da) 2006-12-13 2011-09-05 Shl Group Ab Autoinjektor
AU2008231910B2 (en) 2007-03-23 2011-04-14 Shl Group Ab Auto injector
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
ATE501749T1 (de) 2007-07-06 2011-04-15 Shl Group Ab Monoinjektor mit doppelfedern
US8038649B2 (en) 2007-09-18 2011-10-18 Shl Group Ab Automatic injection device with needle insertion
CN101980716B (zh) * 2008-03-31 2012-11-21 株式会社资生堂 血管成熟化、正常化或稳定化剂以及皱纹防止和/或改善剂
AU2009249848B2 (en) 2008-05-20 2012-03-29 Shl Group Ab Device for a medicament delivery device
CN102112165B (zh) 2008-06-11 2013-05-29 Shl集团有限责任公司 药物输送设备
JP4970594B2 (ja) * 2008-06-18 2012-07-11 株式会社 資生堂 リンパ管の安定化剤
WO2010010689A1 (ja) * 2008-07-22 2010-01-28 株式会社メニコン コンタクトレンズ用液剤
EP2378609A1 (en) 2008-12-22 2011-10-19 Fujikura, Ltd. Film antenna and method for manufacturing the same
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
CN108635350A (zh) 2009-01-12 2018-10-12 爱尔皮奥治疗有限公司 治疗血管渗漏综合征的方法
SG10201505672TA (en) 2009-07-06 2015-09-29 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
TWI393578B (zh) 2009-07-07 2013-04-21 Shl Group Ab 注射裝置
TW201105363A (en) * 2009-07-14 2011-02-16 Univ Yamagata Eye drop for macular edema treatment
MY160066A (en) 2009-11-06 2017-02-15 Aerpio Therapeutics Inc Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
JP2011201811A (ja) * 2010-03-25 2011-10-13 Shiseido Co Ltd Ｔｉｅ２活性化剤、血管の成熟化、正常化又は安定化剤、リンパ管安定化剤並びにしわ防止・改善剤及びむくみ改善・予防剤
US20110319455A1 (en) 2010-04-19 2011-12-29 Bruce Steven Klein Antifungal Treatment
WO2011134056A1 (en) * 2010-04-28 2011-11-03 Sunnybrook Health Sciences Centre Methods and uses of tie2 binding and/or activating agents
US20180092883A1 (en) 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
KR101823924B1 (ko) * 2010-10-07 2018-01-31 에르피오 세러퓨틱스 인코포레이티드 안구 부종, 신생혈관화 및 관련 질환의 치료를 위한 조성물 및 방법
EP2647385A4 (en) * 2010-12-02 2014-04-30 Maruzen Pharm Co Ltd TIE2 ACTIVATOR, VASCULAR ENDOTHELIAL CELL GROWTH FACTOR (VEGF), ANTI-ANGIOGENESIS AGENT, MEANS FOR REINFORCING BLOOD VESSELS, MEANS FOR THE NORMALIZATION OF BLOOD VESSELS, DEVICES FOR STABILIZING BLOOD VESSELS AND PHARMACEUTICAL COMPOSITION
CN102532042A (zh) * 2010-12-30 2012-07-04 上海医药工业研究院 一种芳基脲类化合物、其中间体及其应用
EP2673049A4 (en) 2011-02-11 2015-04-08 Psivida Inc METHOD FOR THE TREATMENT OF MOLECULAR SOILS WITH ANTIOTE THERAPEUTICS
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
CA2850824C (en) 2011-10-13 2023-01-03 Aerpio Therapeutics, Inc. Treatment of ocular disease
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
ES2928162T3 (es) * 2013-03-15 2022-11-15 Eyepoint Pharmaceuticals Inc Composiciones, formulaciones y métodos para tratar enfermedades oculares
WO2015002893A1 (en) 2013-07-02 2015-01-08 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
EP3107542B1 (en) 2014-02-19 2019-05-01 Aerpio Therapeutics, Inc. Process for preparing n-benzyl-3-hydroxy-4-substituted-pyridin-2-(1h)-ones
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9719135B2 (en) * 2014-07-03 2017-08-01 Mannin Research Inc. Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system

Similar Documents

Publication Publication Date Title
JP2016516068A5 (enExample)
JP2018528273A5 (enExample)
Fernandez et al. N-Succinyl-(β-alanyl-l-leucyl-l-alanyl-l-leucyl) doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity
US20050085446A1 (en) Fluoroquinolone formulations and methods of making and using the same
JP6968921B2 (ja) 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション
JP2018518537A5 (enExample)
JP2015503635A (ja) フマギリン誘導体ｐｈｆ複合体の医薬品配合物
AU2014273983A1 (en) Cyclodextrin-based polymers for the therapeutic delivery
US20190142957A1 (en) Stable compositions of pegylated carfilzomib compounds
JP2019511497A5 (enExample)
US20220226444A1 (en) Formulations of fosaprepitant and aprepitant
JP2017506640A5 (enExample)
RU2018101473A (ru) Депо-препарат, содержащий сложный эфир лимонной кислоты
JP2024112842A (ja) Ｍｃｌ１タンパク質を阻害する化合物を投与するための製剤及び投与量
JP2020526497A (ja) 合成バイオコンジュゲート
CN110876259A (zh) 注射用组合物
US20070049552A1 (en) Fluoroquinolone formulations and methods of making and using the same
JP2013532664A5 (enExample)
US20180015170A1 (en) Cyclodextrin-based polymers for therapeutic delivery
JP2018536650A5 (enExample)
ES2749053T3 (es) Polimixinas de baja sustitución y sus composiciones
JP6931257B2 (ja) レバミピドを含有する新規ドライアイ治療用点眼組成物及びその可溶化及び安定化方法
CN105267214B (zh) N-杂芳基苯胺类化合物作为制备抗肿瘤药物的应用
CN103501782A (zh) 黄斑变性预防或治疗用药物组合物
KR20090040299A (ko) 특별히 표적화된 국소 투여를 위한 주사용 약제학적 조성물